"Our next-generation SynCon® vaccines and CELLECTRA® electroporation delivery devices have demonstrated best-in-class T-cell responses for HIV..."
This addition of Pennvax-B trials in today's PR (which was for hepC vaccines) shows that nothing has changed from the previous positive results until now.
INOVIO remains stable to the "best-in-class T-cell responses for HIV" as we wait the medical journal publication.
Chrontech will have to redo this short trial using the same methods from phase I, that is 4 doses over 24 weeks, or add in a high dose. Where did the come up with a 2 dose treatment?
A strong T-cell response is good news to me as it was not Inovios vaccine to begin with.